Pipeline

Traverse Biotech has a growing pipeline of cutting-edge technologies with the potential to treat some of the most challenging diseases. We are developing these highly differentiated immuno-oncology products that are derived from validated therapeutic platforms.

CD3 X ROR2 DuoBodyTM in Multiple Oncology Indications

Targeting Innate Immunity in Oncology and Aging

Additional Technologies

ROR2 as a T Cell Engager Target

ROR2 is an attractive novel target linked to tumor-dependent pathways and processes

Expressed during embryonic development.
Reappears during cancer development
Activates multiple pro-tumor pathways

Relevant publications on ROR2:

Debebe et al., "Ror2 as a therapeutic target in cancer," Pharmacology & therapeutics (2015).
Babin et al., “De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as a target for cancer cells,” Mol Cancer (2022).
Grither, Whitney R., et al. "ROR2/Wnt5a signaling regulates directional cell migration and early tumor cell invasion in ovarian cancer." Molecular Cancer Research (2024).

Read more about the Duobody platform here.

Pipeline

More on the Science behind our Lead Product

ROR2 as a T Cell Engager Target